05:13 PM EDT, 05/19/2025 (MT Newswires) -- Zymeworks ( ZYME ) said Monday that new preclinical data for its experimental respiratory inflammation drug ZW1528 has shown positive results.

The drug targets two proteins involved in inflammation and blocks their signals to reduce immune responses, the company said.

In lab studies, ZW1528 worked well at stopping inflammation in immune cells taken from chronic obstructive pulmonary disease patients and also showed strong results in animal tests involving lung inflammation caused by dust mites, it added.

The drug remained stable at high concentrations, supporting the option of administering it through subcutaneous injection, according to the company.